What Is 2A self-cleaving peptides

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 15, 2026

Quick Answer: 2A self-cleaving peptides are short protein sequences, typically 18–22 amino acids long, derived from picornaviruses that enable co-translational cleavage during protein expression. They are widely used in biotechnology to express multiple proteins from a single mRNA transcript, with cleavage efficiencies often exceeding 90% in mammalian cells.

Key Facts

2A peptides are 18–22 amino acids long and originate from picornaviruses like FMDV and P2A from porcine teschovirus-1
Cleavage efficiency of 2A peptides can reach >95% in optimized mammalian expression systems
The first 2A peptide (F2A) was identified in 1999 by Ryan et al. in the foot-and-mouth disease virus
2A peptides enable polycistronic gene expression in eukaryotes, bypassing the 'one mRNA, one protein' rule
Common 2A types include F2A, E2A, P2A, and T2A, each with varying cleavage efficiencies across species

Overview

2A self-cleaving peptides are molecular tools used in genetic engineering to produce multiple proteins from a single mRNA transcript. Found naturally in certain viruses, particularly picornaviruses, these peptides enable the ribosome to 'skip' a peptide bond during translation, effectively separating two linked proteins.

These peptides are not enzymes and do not hydrolyze bonds like proteases. Instead, they induce a ribosomal 'skip' mechanism, allowing co-translational cleavage. This makes them invaluable in synthetic biology and gene therapy applications where coordinated expression of multiple proteins is required.

Length: 2A peptides are typically 18–22 amino acids long, compact enough to be included in gene constructs without excessive genetic load.
Origin: They originate from picornaviruses, including foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), and porcine teschovirus-1 (P2A).
Mechanism: They function through ribosome skipping, a process where the ribosome fails to form a peptide bond at the end of the 2A sequence, releasing the upstream protein.
Efficiency: Cleavage efficiency ranges from 80% to over 95%, depending on the 2A variant and host cell type, with P2A and T2A showing high performance in mammalian cells.
Applications: Widely used in gene therapy vectors, CAR-T cell engineering, and multi-gene expression systems where stoichiometric protein production is critical.

How It Works

The function of 2A peptides hinges on a unique translational event rather than enzymatic activity. During protein synthesis, the ribosome translates the entire polycistronic mRNA, but at the end of the 2A sequence, a conformational change prevents peptide bond formation.

Ribosome Skipping: At the C-terminus of the 2A peptide, the ribosome fails to form a peptide bond between glycine and proline residues, leading to release of the upstream protein while translation continues.
C-Terminal Residue: The final glycine residue in the 2A sequence is essential for cleavage and remains attached to the upstream protein, potentially affecting function.
Downstream Protein: The downstream protein begins with a proline residue, which is critical for the ribosomal skip mechanism to occur efficiently.
No Enzymatic Action: Unlike proteases, 2A peptides do not cleave themselves; instead, they exploit ribosomal dynamics to achieve separation.
Residual Sequences: Cleavage leaves short peptide remnants (typically 1–18 amino acids) on both the upstream and downstream proteins, which may require engineering to avoid interference.
Sequence Context: Flanking sequences and codon optimization significantly impact cleavage efficiency, with mammalian systems often requiring tailored designs.

Comparison at a Glance

Several 2A variants are commonly used in research, each with distinct cleavage efficiencies and host compatibility.

2A Type	Source Virus	Length (aa)	Cleavage Efficiency	Best-Performing System
F2A	Foot-and-mouth disease virus	18	80–85%	Mammalian cells
E2A	Equine rhinitis A virus	22	70–75%	Plant systems
P2A	Porcine teschovirus-1	19	90–95%	Human and mouse cells
T2A	Thosea asigna virus	20	85–90%	Broad eukaryotic use
Combined 2A	Synthetic	Variable	Up to 98%	Multi-gene vectors

These differences guide researchers in selecting the optimal 2A peptide for their experimental system. For example, P2A is often preferred in mammalian gene therapy due to its high efficiency, while T2A offers reliable performance across diverse species.

Why It Matters

The development and refinement of 2A peptides have significantly advanced genetic engineering and biomedical research. Their ability to enable precise, coordinated expression of multiple proteins from a single transcript has broad implications for both basic science and clinical applications.

Gene Therapy: Enables delivery of multiple therapeutic genes in a single viral vector, reducing immune response and improving transduction efficiency.
CAR-T Cells: Used to co-express chimeric antigen receptors and selection markers, streamlining the manufacturing of cancer immunotherapies.
Stem Cell Research: Facilitates the expression of reprogramming factors like Oct4, Sox2, Klf4, and c-Myc from a single construct.
Vaccine Development: Allows co-expression of viral antigens and adjuvants in DNA or viral vector vaccines.
Protein Tagging: Permits the addition of fluorescent or affinity tags without separate promoters, simplifying protein detection and purification.
Reduced Genetic Load: Minimizes the need for multiple promoters and polyA signals, conserving space in size-limited vectors like AAV.

As synthetic biology evolves, 2A peptides remain a cornerstone technology for multi-gene expression, offering a compact, efficient alternative to traditional IRES elements and dual-promoter systems.